Valproate inhibits the conversion of testosterone to estradiol and acts as an apoptotic agent in growing porcine ovarian follicular cells

Epilepsia

Volumn 44, Issue 8, 2003, Pages 1014-1021

  Taubøll, Erik ^a   Gregoraszczuk, Ewa L ^b   Kołodziej, Anna ^b   Kajta, Małgorzata ^c   Ropstad, Erik ^d  

^a UNIVERSITY OF OSLO   (Norway)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

Author keywords

Apoptosis; Caspase 3; Estrogen; FSH; LH; Polycystic ovaries; Testosterone; Valproate

Indexed keywords

AROMATASE; CASPASE 3; CYTOCHROME P450; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE; VALPROIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; EPILEPSY; ESTROGEN RELEASE; HORMONE ACTION; HYPERANDROGENISM; LONG TERM EXPOSURE; NONHUMAN; OVARY FOLLICLE CELL; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; STEROIDOGENESIS; TESTOSTERONE RELEASE;

ANIMALS; ANTICONVULSANTS; APOPTOSIS; AROMATASE INHIBITORS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GRANULOSA CELLS; LUTEINIZING HORMONE; OVARY; SECRETORY RATE; SWINE; TESTOSTERONE; THECA CELLS; VALPROIC ACID;

EID: 0042071485     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2003.60702.x     Document Type: Article

References (53)

1. Rowan AJ. Valproate. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:1599-607.
2. Muzina DJ, El-Sayegh S, Calabrese JR. Antiepileptic drugs in psychiatry: focus on randomized controlled trial. Epilepsy Res 2002;50:195-202.
3. Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine. CNS Drugs 2002;16:611-34.
4. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
5. Isojärvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
6. Isojärvi JIT, Taubøll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001:111:290-6.
7. Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-6.
8. Herzog AG. Polycystic ovarian syndrome in women with epilepsy: epileptogenic or iatrogenic? Ann Neurol 1996;39:559-60
9. Genton P, Bauer J, Duncan S, et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001;42:295-304.
10. Herzog AG, Schachter SC. Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia 2001;42:311-5.
11. Isojärvi JIT, Taubøll E, Tapanainen J, et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 2001;42:290-304.
12. O'Donovan C, Kusumakar V, Graves GR, et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002;63:322-30.
13. Taubøll E, Isojärvi JIT, Flinstad Harbo H, et al. Long-term valproate treatment induces changes in ovarian morphology and serum sex steroid hormone levels in female Wistar rats. Seizure 1999;8:490-3.
14. Røste LS, Tauboll E, Berner A, et al. Valproate, but not lamotrigine, induced ovarian morphological changes in Wistar rats. Exp Toxicol Pathol 2001;52:545-52.
15. Rø LS, Taubøll E, Isojärvi JIT, et al. Effects of chronic treatment on reproductive endocrine hormones in female and male Wistar rats. Reprod Toxicol 2002;16:767-73.
16. Gregoraszczuk EL, Wojtowicz AK, Tauboll E, et al. Valproate-induced alterations in testosterone, estradiol and progesterone secretion from porcine follicular cells isolated from small- and medium-sized ovarian follicles. Seizure 2000;9:480-5.
17. Taubøll E, Wójtowicz AK, Ropstad E, et al. Valproate irreversibly alters steroid secretion patterns from porcine follicular cells in vitro. Reprod Toxicol 2002;16:319-25.
18. Gregoraszczuk EL, Skałka M. Thyroid hormone as a regulator of basal and hCG-stimulated steroidogenesis by cultured porcine theca and granulosa cells isolated at different stages of the follicular phase. Reprod Fertil Dev 1996;8:961-7.
19. Liu X, Andoh K, Yokota H, et al. Effects of growth hormone, activin, and follistatin on the development of preantral follicle from immature female mice. Endocrinology 1998;139:2342-7.
20. Stoklosowa S, Bahr J, Gregoraszczuk EL. Some morphological and functional characteristics of cells of the porcine theca interna in tissue culture. Biol Reprod 1978;19:712-9.
21. Fitzpatrick SL, Richards JS. Regulation of cytochrome P450 aromatase messenger ribonucleic acid and activity by steroids and gonadotropins in rat granulosa cells. Endocrinology 1991;129:145-262.
22. Lambert A, Harris SD, Knaggs P, et al. Improved FSH sensitisation and aromatase assay in human granulosa-lutein cells. Mol Hum Reprod 2000;6:677-80.
23. 3H]thymidyne incorporation assay. J Immunol Methods 1994;170:211-24.
24. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
25. 3H-thymidine incorporation assay. J Clin Lab Anal 1995;9: 89-95.
26. Mhashilkar AM, Schrock RD, Hindi M, et al. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol Med 2001;7:271-82.
27. Kolodziejczyk J, Gregoraszczuk EL, Leibovich H, et al. Different action of ovine GH on porcine theca and granulosa cells proliferation and insulin-like growth factor I- and II-stimulated estradiol production. Reprod Biol 2001;1:33-41.
28. Gore-Langton RE, Armstrong DT. Follicular steroidogenesis and its control. In: Knobil E, Neil JD, eds. The physiology of reproduction. New York: Raven Press, 1993;1:571-627.
29. Erickson GF, Magoffin DA, Dyer CA, et al. The ovarian androgen producing cells: a review of structure/function relationships. Endocrinol Rev 1985;6:371-99.
30. Stadnicka A, Stoklosowa S. Enzyme histochemistry of cultured ovarian cells, II: Histochemistry of porcine theca interna cells in tissue culture. Z Mikrosk Anat Forsch 1976;90:458-68.
31. Gilling-Smith C, Story H, Rogers V, et al. Evidence for primary abnormality of thecal cell steroidogenesis in the polycistic ovary syndrome. Clin Endocrinol (Oxf) 1997;47:93-9.
32. Nelson VL, Quin K, Rosenfield RL, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:5925-33.
33. Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21:52-8.
34. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988;29:612-9.
35. Bilo L, Meo R, Valentino R, et al. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 2001;86:2950-6.
36. Cramer JA, Jones EE. Reproductive function in epilepsy. Epilepsia 1991;32(suppl 6):19-26.
37. Cummings LN, Giudice L, Morrell MJ. Ovulatory function in epilepsy. Epilepsia 1995;36:355-9.
38. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61.
39. Tamura T, Kitawaki J, Yamamoto T, et al. Immunohistochemical localization of 17α-hydroxylase/C17-20 lyase and aromatase cytochrome P450 in polycystic human ovaries. J Endocrinol 1993;139:503-9.
40. Wulff K, Flachs H, Würtz-Jørgensen A, et al. Clinical and pharmacological aspects of valproate sodium. Epilepsia 1977;18:149-57.
41. Schmidt D. Fluctuations of dipropyl acetate plasma levels with one and three daily doses. Pharmacol Weekly 1977;112:285-7.
42. Spiller HA, Krenzelok EP, Klein-Schwartz W, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. Clin Toxicol 2000;38:755-60.
43. Los M, Burek CJ, Stroh C, et al. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discovery Today 2003;8:67-77.
44. Ishizaki Y, Jacobson MD, Raff MC. A role for caspases in lens fiber differentiation. J Cell Biol 1998;140:153-8.
45. Widlak P. The DFF40/CAD endonuclease and its role in apoptosis. Acta Biochim Pol 2000;47:1037-44.
46. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 1999;6:1028-42.
47. Thornberry NA. Caspases: a decade of death research. Cell Death Differ 1999;6:1023-7.
48. Hunter MG, Wiesak T. Evidence for and implications of follicular heterogeneity in pigs. J Reprod Fertil Suppl 1990;40:163-77.
49. Billing H, Futura I, Hsueh AJ. Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. Endocrinology 1993;133:2204-12.
50. Zhang Y, Tounekti O, Akerman B, et al. 17-Beta-estradiol induces an inhibitor of active caspases. J Neurosci 2001;15:RC176.
51. Cregan SP, MacLaurin JG, Craig CG, et al. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J Neurosci 1999;19:7860-9.
52. Kipp JL, Ramirez VD. Effect of estradiol, diethylstilbestrol, and resveratrol on F0F1-ATPase activity from mitochondrial preparations of rat heart, liver, and brain. Endocrine 2001;15:165-75.
53. Green PS, Simpkins JW. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 2000;18:34758.